Lilly's Mounjaro wins a CV nod, Teva buys BioXcel's assets, AusperBio raises $120M and Samsung Biologics preps a $2.2B raise.
Plus news about AusperBio and Samsung Biologics.
Eli Lilly’s Mounjaro wins heart approval: The blockbuster drug, whose generic name is tirzepatide, was
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
In their high-profile competition in the diabetes and obesity markets, Eli Lilly has proven adept at playing catch-up with Novo…
The FDA has approved tirzepatide for reduction of cardiovascular risk in adults with type 2 diabetes, Eli Lilly…
The diabetes drug, already the top-prescribed branded type 2 diabetes medicine in the U.S., showed an 8% lower rate of major…
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
The new indication for Eli Lilly's drug is for people with Type 2 diabetes.
Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers' first choice for patients with Type 2…
Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients
Mounjaro approved to reduce cardiovascular events in adults with diabetes
FDA approves Mounjaro to lower heart attack and stroke risk
FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Mounjaro Is Now Approved to Lower the Risk of Heart Events
Eli Lilly diabetes drug wins FDA approval to lower cardiovascular risks
Weight-loss drugs could help treat other health conditions. Here’s what could be next
Regulador dos EUA aprova Mounjaro, da Eli Lilly, para reduzir risco cardiovascular
AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
